Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.
The liver X receptors LXRalpha and LXRbeta play critical roles in maintaining lipid homeostasis by functioning as transcription factors that regulate genetic networks controlling the transport, catabolism, and excretion of cholesterol. The studies described in this report examine the individual anti-atherogenic activity of LXRalpha and LXRbeta and determine the ability of each subtype to mediate the biological response to LXR agonists. Utilizing individual knockouts of LXRalpha and LXRbeta in the Ldlr(-/-) background, we demonstrate that LXRalpha has a dominant role in limiting atherosclerosis in vivo. Functional studies in macrophages indicate that LXRalpha is required for a robust response to LXR ligands, whereas LXRbeta functions more strongly as a repressor. Furthermore, selective knockout of LXRalpha in hematopoietic cells and rescue experiments indicate that the anti-atherogenic activity of this LXR subtype is not restricted to macrophages. These studies indicate that LXRalpha plays a selective role in limiting atherosclerosis in response to hyperlipidemia.
Bischoff
Eric D
ED
Exelixis, Inc., San Diego, CA, USA.
Daige
Chris L
CL
Petrowski
Mary
M
Dedman
Harry
H
Pattison
Jennifer
J
Juliano
Joseph
J
Li
Andrew C
AC
Schulman
Ira G
IG
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism*; D001854:Bone Marrow Cells / Q000378:metabolism; D004198:Disease Susceptibility / Q000378:metabolism; D005786:Gene Expression Regulation; D055786:Gene Knockout Techniques; D000071518:Liver X Receptors; D008264:Macrophages / Q000378:metabolism; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D057093:Orphan Nuclear Receptors / Q000819:agonists / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D011973:Receptors, LDL / Q000172:deficiency* / Q000235:genetics*
D000071518:Liver X Receptors; C000605214:Nr1h3 protein, mouse; D057093:Orphan Nuclear Receptors; D011973:Receptors, LDL
Cell. 2008 Jul 11;134(1):97-111
18614014
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7604-9
12032330
Mol Endocrinol. 2003 Jun;17(6):985-93
12690094
J Lipid Res. 2009 Apr;50 Suppl:S15-27
18974038
Circulation. 2002 Aug 27;106(9):1147-53
12196343
J Biol Chem. 2003 May 2;278(18):15565-70
12601003
Curr Opin Cardiol. 2007 Jul;22(4):368-72
17556891
Cell. 2001 Feb 23;104(4):503-16
11239408
Cell. 1998 May 29;93(5):693-704
9630215
J Clin Invest. 2007 Aug;117(8):2337-46
17657314
J Lipid Res. 1995 Nov;36(11):2320-8
8656070
J Clin Invest. 2006 Mar;116(3):607-14
16511593
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):527-33
18096827
Mol Pharmacol. 2006 Oct;70(4):1340-9
16825483
Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):135-42
15539622
Mol Cell Biol. 2003 Aug;23(16):5780-9
12897148
Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):507-12
11149950
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2009-15
18787185
FEBS Lett. 2003 Feb 11;536(1-3):6-11
12586329
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11896-901
12193651
Genes Dev. 2000 Nov 15;14(22):2819-30
11090130
J Lipid Res. 2005 Oct;46(10):2182-91
16024916
Nature. 2008 Jul 24;454(7203):470-7
18650918
Science. 2000 Sep 1;289(5484):1524-9
10968783
J Biol Chem. 2000 Sep 8;275(36):28240-5
10858438
J Lipid Res. 2007 Dec;48(12):2571-8
17720994
Genes Dev. 2000 Nov 15;14(22):2831-8
11090131
Biochem Pharmacol. 2006 Feb 14;71(4):453-63
16325781